King Pharmaceuticals launches two new dosage strengths of pain drug

Posted on: Fri, 06 Feb 2009 09:27:00 EST


Symbols: KG
Feb 06, 2009 (Datamonitor via COMTEX) --
KG | Quote | Chart | News | PowerRating -- King Pharmaceuticals, a vertically integrated pharmaceutical company, has launched two new FDA-approved dosage strengths for Avinza.

The new dosing strengths, 45mg and 75mg, complement the currently available 30mg, 60mg, 90mg and 120mg dosages. Avinza is a long-acting opioid for patients with moderate to severe chronic pain who require around-the-clock pain relief for an extended period of time, the company said.

Avinza is an extended-release form of morphine allowing for once-daily dosing. Avinza is covered by a formulation patent that extends through November 2017.

Eric Carter, chief science officer of King, said: "These new capsule strengths provide physicians with additional options that may enable more customized approaches to treating people with chronic pain."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon

For full details on King Pharmaceuticals Inc (KG) KG. King Pharmaceuticals Inc (KG) has Short Term PowerRatings at TradingMarkets. Details on King Pharmaceuticals Inc (KG) Short Term PowerRatings is available at This Link.

UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday February 11 04:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.